GLP-1 users are suing over vision loss: What does the evidence really show?Dozens of patients have taken legal action against drug manufacturers, filing personal injury lawsuits that allege they were not adequately...
Ozempic maker Novo Nordisk sets sights on hair-loss marketThe condition is part of a list of areas, including addiction and menopause, where Novo sees potential overlap with either its core scienti...
Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugsFacing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating ...
Novo partners with Anthropic to speed up drug development with ClaudeThe Danish drugmaker will initially test Anthropic models and Claude Science in its research and development workflows, and address scienti...
Eli Lilly’s Mounjaro wins FDA approval for a major new cardiovascular benefitEli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes ...
Eli Lilly launches oral weight-loss pill Foundayo in UKEli Lilly has launched its oral weight management pill Foundayo in the United Kingdom. This new treatment, chemically known as orforglipron...
Nestle looks to develop new products to serve users of weight-loss drugsNestle is developing specialized products for GLP-1 weight-loss drug users. Artificial intelligence aids in analyzing research and identify...
UK first in Europe to approve Eli Lilly oral weight loss drugBritain has become the first country in Europe to approve orforglipron, the oral weight loss and diabetes treatment developed by US company...
Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetesBritain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the ...
Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipelineNovo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline afte...
Wegovy pill explained: Pricing, doses, and where to get Novo Nordisk's oral GLP-1 weight loss drugWegovy pill: Novo Nordisk is launching the first oral GLP-1 pill for weight loss, offering a more affordable alternative to injections. The...
Slimmer price tag helps Wegovy sales gain weightNovo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...
Hims stock tanks over 20% after Wegovy deal collapse — why Novo Nordisk’s breakup over weight loss drugs is shaking up Wall StreetHims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. Th...
Weight loss drug Wegovy can help fight deadly liver disease MASH, claims new studyA latest study has shown promising results in people suffering from metabolic dysfunction-associated steatohepatitis (MASH), an advanced fo...
Novo Nordisk readies to bring weight-loss drug Wegovy to IndiaDanish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform El...
Novo Nordisk India head eyes 2026 launch for obesity drug Wegovy, warns against copycatsNovo Nordisk plans to bring its weight-loss drug, Wegovy, to India in 2026. The company aims to secure regulatory approvals and ensure suff...
Biggest pharma blockbuster? All about Wegovy, Novo Nordisk's obesity drug, that cuts risk of heart attacks and strokes by 20%In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss...